Significance of miR-122 -and miR- 150 in the pathogenicity of hepatitis B infection
Abstract
Background: HBV, a contagious infection, causes chronic hepatitis, cirrhosis, and hepatocellular cancer in many people. The WHO estimates that 2 billion people are exposed to HBV annually, depending on when. The Hepadnaviridae family virus has an unfinished 3.2-kilobase double-stranded DNA molecule. Increased ALT, AST, and HBsAg positive or HBV DNA viral load are used to identify the illness. Despite global immunization campaigns, nations with low vaccination coverage and no diagnosis remain concerned. The worldwide HBV burden remains high. MicroRNAs (miRNAs) bind to mRNAs after transcription to govern gene expression, hepatitis B virus replication, and extracellular matrix development.
Methods: Sixty six Iraqi HBV patients were involved in a case-sectional control study. From September 2021 to February 2022, blood samples were taken from Al-Yarmook Teaching Hospital and Central Public Health Laboratory in Baghdad. ELISA verified HBV markers, HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb in all samples, and real-time PCR estimated viral load from DNA. The research found that miR122 and miR150 gene expressions affect HBV fibrosis severity.
Results: The gene expression of miR-122 and miR-150 was found using RT-PCR after normalization with Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a common housekeeping gene. The analysis of variance found substantial differences between patients and controls. The research found a considerable downregulation of miRNA-122 and miRNA-150 in HBV-infected individuals.
Conclusions: Depending on HBV severity, miRNA levels may vary. HBV patients, especially those with fibrosis and chronic HBV, have reduced miR122 and miR150. MiR-122 and miR-150 may be interesting HBV diagnostic, fibrosis progression, and therapeutic targets.
Keywords: Hepatitis B virus; MicroRNAs (miRNAs); RT-PCR; Primers; Gene expression; Liver disease
Full Text:
PDFReferences
Lampertico P, Agarwal K, Berg T, Buti M, Janssen HL, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology, (2017); 67(2): 370-398.
Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. International journal of medical sciences, (2005); 2(1): 50-57.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of viral hepatitis, (2004); 11(2): 97-107.
Trépo C, Chan HL, Lok A. Hepatitis B virus infection. The Lancet, (2014); 384(9959): 2053-2063.
Kim H, Lee S-A, Kim B-J. X region mutations of hepatitis B virus related to clinical severity. World journal of gastroenterology, (2016); 22(24): 5467-5478.
Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nature reviews genetics, (2010); 11(9): 597-610.
Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology, (2008); 134(6): 1655-1669.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, (2004); 116(2): 281-297.
Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, et al. Widespread changes in protein synthesis induced by microRNAs. Nature, (2008); 455(7209): 58-63.
Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, et al. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World journal of hepatology, (2018); 10(9): 558-570.
Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Developmental cell, (2006); 11(4): 441-450.
Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clinical chemistry, (2010); 56(12): 1830-1838.
Russo A, Potenza N. Antiviral effects of human microRNAs and conservation of their target sites. FEBS letters, (2011); 585(16): 2551-2555.
Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, et al. Micro‐RNA profiling reveals a role for miR‐29 in human and murine liver fibrosis. Hepatology, (2011); 53(1): 209-218.
Zhang H, Li Q-Y, Guo Z-Z, Guan Y, Du J, et al. Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World journal of gastroenterology, (2012); 18(37): 5188-5196.
Yu F, Zhou G, Li G, Chen B, Dong P, et al. Serum miR-181b is correlated with hepatitis B virus replication and disease progression in chronic hepatitis B patients. Digestive diseases and sciences, (2015); 602346-602352.
Li L-M, Hu Z-B, Zhou Z-X, Chen X, Liu F-Y, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer research, (2010); 70(23): 9798-9807.
Qi P, Cheng S-q, Wang H, Li N, Chen Y-f, et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PloS one, (2011); 6(12): e28486.
Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. Drug news & perspectives, (2010); 23(8): 498-508.
Anwar SL, Lehmann U. MicroRNAs: emerging novel clinical biomarkers for hepatocellular carcinomas. Journal of clinical medicine, (2015); 4(8): 1631-1650.
Szabo G, Bala S. MicroRNAs in liver disease. Nature reviews Gastroenterology & hepatology, (2013); 10(9): 542-552.
Hu J, Xu Y, Hao J, Wang S, Li C, et al. MiR-122 in hepatic function and liver diseases. Protein & cell, (2012); 3(5): 364-371.
Tsai W-C, Hsu S-D, Hsu C-S, Lai T-C, Chen S-J, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. The Journal of clinical investigation, (2012); 122(8): 2884-2897.
Li J, Ghazwani M, Zhang Y, Lu J, Li J, et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. Journal of hepatology, (2013); 58(3): 522-528.
Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, et al. Serum microRNA‐122 levels in different groups of patients with chronic hepatitis B virus infection. Journal of viral hepatitis, (2012); 19(2): e58-e65.
Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. science, (2005); 309(5740): 1577-1581.
Kumar S, Chawla YK, Ghosh S, Chakraborti A. Severity of Hepatitis C Virus (Genotype‐3) Infection Positively Correlates with Circulating MicroRNA‐122 in Patients Sera. Disease Markers, (2014); 2014(1): 435-476.
Zheng J, Lin Z, Dong P, Lu Z, Gao S, et al. Activation of hepatic stellate cells is suppressed by microRNA-150. International journal of molecular medicine, (2013); 32(1): 17-24.
DOI: http://dx.doi.org/10.62940/als.v12i1.2130
Refbacks
- There are currently no refbacks.